Sanofi (SNY) Q3 2024 Earnings Call Transcript Summary
Sanofi (SNY) Q3 2024 Earnings Call Transcript Summary
Gross margin improved by a full percentage point this quarter, influenced by positive mix effects and offset by currency impacts due to Aubagio's loss of exclusivity.The following is a summary of the Sanofi (SNY) Q3 2024 Earnings Call Transcript:
以下是賽諾菲安萬特（SNY）2024年第三季度業績會文本摘要：
Financial Performance:
金融業績：
Sanofi reported Q3 2024 sales of EUR 13.4 billion, a 16% increase in constant exchange rates.
Business EPS guidance for 2024 was raised, reflecting strong business momentum and commitment to stakeholder value.
Gross margin improved by a full percentage point this quarter, influenced by positive mix effects and offset by currency impacts due to Aubagio's loss of exclusivity.
賽諾菲安萬特報告，2024年第三季度銷售額爲134億歐元，在固定匯率下增長了16%。
業務每股收益2024年的指導預期有所提高，反映了強勁的業務勢頭和對利益相關者價值的承諾。
本季度毛利率提高了一個百分點，受積極的組合效應影響，受到奧巴吉失去排他性帶來的貨幣影響所抵消。
Business Progress:
業務進展：
Dupixent sales reached EUR 3.5 billion in Q3, driven by volume growth across all geographies and indications, reflecting its market leadership in biologic therapies.
Vaccines business grew by 26% due to phasing in flu and Beyfortus sales, with Beyfortus showing exceptional market uptake in its second season.
Strategic acquisition of Qunol in the US enhanced Sanofi's presence in the consumer healthcare market.
Q3杜比顯達銷售額達到35億歐元，受到各地區和適應症成交量增長的推動，反映了其在生物製劑治療領域的市場領導地位。
疫苗業務由於流感和比福託斯銷售增長，增長了26％，比福託斯在第二個銷售季顯示出異常的市場吸收力。
賽諾菲安萬特通過在美國戰略收購Qunol增強了在消費者保健市場的影響力。
Opportunities:
機會：
The global rollout of Beyfortus and recent approvals for Dupixent's COPD indication offer significant near-term growth opportunities.
Continued geographic expansions and upcoming product launches in existing and new indications are set to drive future sales and market penetration.
Beyfortus在全球的推廣和Dupixent的COPD適應症最近獲批，爲有重大增長機會提供了重要的近期增長機會。
持續的地理擴張和現有及新適應症的即將推出的產品，將推動未來銷售和市場滲透。
Risks:
風險：
Potential market competition for Beyfortus could affect growth projections, demanding strategic responses to maintain market leadership.
Beyfortus潛在的市場競爭可能會影響增長預期，要求制定戰略應對以保持市場領先地位。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
